Emerging phenotypes of pulmonary hypertension associated with COPD: a field guide

Agustín Roberto García and Lucilla Piccari

Purpose of review
Pulmonary hypertension (PH) is a common complication of chronic obstructive lung disease (COPD), but clinical presentation is variable and not always ‘proportional’ to the severity of the obstructive disease. This review aims to analyze heterogeneity in clinical features of PH-COPD, providing a guide for diagnosis and management according to phenotypes.

Recent findings
Recent works have focused on severe PH in COPD, providing insights into the characteristics of patients with predominantly vascular disease. The recently recognized ‘pulmonary vascular phenotype’, characterized by severe PH and mild airflow obstruction with severe hypoxemia, has markedly worse prognosis and may be a candidate for large trials with pulmonary vasodilators. In severe PH, which might be best described by a pulmonary vascular resistance threshold, there may also be a need to distinguish patients with mild COPD (pulmonary vascular phenotype) from those with severe COPD (‘Severe COPD-Severe PH’ phenotype).

Summary
Correct phenotyping is key to appropriate management of PH associated with COPD. The lack of evidence regarding the use of pulmonary vasodilators in PH-COPD may be due to the existence of previously unrecognized phenotypes with different responses to therapy. This review offers the clinician caring for patients with COPD and PH a phenotype-focused approach to diagnosis and management, aimed at personalized care.

Keywords
chronic obstructive pulmonary disease, diagnosis, phenotypes, pulmonary hypertension, treatment

INTRODUCTION
Pulmonary hypertension (PH) is a complication of chronic obstructive pulmonary disease (COPD) [1] associated with increased morbidity [2,3] and mortality [4*,5,6]. Prevalence, reported to be up to 90% [7–9], varies widely according to the different study populations (mild COPD to pretransplant stages) and different definitions of PH (including postcapillary PH and diverse thresholds for PH diagnosis) [9,10]. The threshold to define PH in lung disease has been lowered [1] to define mild-moderate PH as mean pulmonary artery pressure (mPAP) ≥21 mmHg in the presence of increased pulmonary vascular resistance (PVR ≥3 wood units, WU) or mPAP ≥25 mmHg, and severe PH as mPAP ≥35 mmHg or mPAP ≥25 mmHg with cardiac index (CI) <2 L/min/m². PH is usually mild to moderate in COPD but is severe in 1–5% of cases [8,11], representing a distinct subgroup with markedly worse prognosis and predominant vascular impairment associated with relatively mild obstructive disease [6,12], which has been described as a ‘pulmonary vascular phenotype’ (PVP) [13]. A paradigm shift is taking place in PH research, aimed at the analysis of phenotypic heterogeneity and ultimately precision medicine [14,15]. This review aims to update and orient the clinician on the changing landscape of COPD associated with PH, providing a guide for diagnosis and management according to phenotype.
**KEY POINTS**

- Pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD) is heterogeneous in both clinical presentation and outcome.
- In patients with severe PH and mild COPD, the magnitude of gas exchange impairment, rather than that of airflow obstruction, may be useful to distinguish COPD with ‘pulmonary vascular phenotype’ from the concurrence of COPD and idiopathic pulmonary arterial hypertension.
- Patients with ‘severe COPD-severe PH’ may need to be distinguished from the ‘pulmonary vascular phenotype’, characterized by mild COPD and severe PH, in future observational studies and clinical trials.
- The correct phenotyping of PH in COPD is key to proper patient management and to designing future research.

**PATHOPHYSIOLOGY**

The loss of pulmonary vessels due to emphysematous destruction and vascular remodeling of small muscular arteries and arterioles are the main mechanisms for PH in COPD [16]. Capillary density in COPD lungs appears to be dependent on PH severity [17]; vascular changes develop in different stages of COPD and in heavy smokers with preserved lung function [18–20]. The main histologic changes are: intimal hyperplasia through proliferation of smooth muscle cells [18,21,22], possibly by dedifferentiation and migration from the media to the intima [23]; medial thickening [24,25]; and the deposition of elastic and collagen fibers; all this produces thickening of the arterial wall and increased pulmonary vascular resistance [26]. The progressive luminal narrowing and loss of smaller distal vessels results in the ‘pruning’ described in CT scan and angiography [27,28], and the loss of distal arterial vasculature is related to right ventricle (RV) enlargement [27].

**PATHOGENESIS: ENVIRONMENTAL FACTORS AND GENETICS**

The mechanisms leading to PH in COPD are related to endothelial dysfunction at early disease stages. Airborne particulates and tobacco smoke are triggers for pulmonary vascular alterations [29], even in patients with normal lung function [16] and prior to emphysema development [20,30,31]. Persistent hypoxia contributes to chronic vasoconstriction and vascular remodeling [1,18,32]. The relationship between pulmonary pressure and arterial oxygen (PaO₂) is variable [9], and vascular alterations related to hypoxia might be partially reversible [33,34]. Finally, genetic heterogeneity might play a role in the development of a PVP in COPD patients. Some gene variants related to pulmonary arterial hypertension (PAH) are probably also implicated in PH and respiratory diseases [35,36]. Genes belonging to the retinol metabolism and extracellular matrix pathways [37] and to T-lymphocyte activation [38] are also implicated in vascular remodeling.

**DIAGNOSTIC WORKUP**

Symptoms of PH are nonspecific and common to COPD: exertional dyspnea, weakness and fatigue [39]. However, symptoms that seem excessive for the degree of obstructive disease should warn of vascular involvement. In advanced disease, more specific symptomatology of progressive right heart failure ensues: chest pain, syncope, peripheral edema, jugular venous dilation, and abdominal distension; however, no individual physical finding can accurately predict PH [40].

Echocardiography is an accessible, noninvasive tool, crucial to corroborate the suspicion of PH. Besides estimating the systolic pulmonary arterial pressure, it allows the assessment of RV morphology and function, right atrium diameter, signs of fluid overload, valvular or other left heart abnormalities which might be the cause of PH, and which are highly prevalent [41] in patients with tobacco exposure [42,43]. Although echocardiography presents technical difficulties in COPD patients [44], it should be performed whenever PH is suspected. Common situations in clinical practice are disproportionate symptoms and/or low diffusing capacity for carbon monoxide (DLCO) with relatively preserved spirometry and lung parenchyma [45]. The size of the main pulmonary artery on computed tomography (CT), together with other signs suggesting RV overload, may suggest PH [3,46,47]. The role of biomarkers is controversial. Brain natriuretic peptide (BNP) or N-terminal pro-BNP are often increased in patients with COPD, reflecting pulmonary vascular and RV remodeling but also left heart dysfunction and other comorbidities [48–50]. A recent work [51] suggests the combination of echocardiographic, blood markers and CT parameters to reliably predict severe PH in COPD. Cardiopulmonary exercise tests are useful to distinguish ventilatory from circulatory limitation associated with PH in COPD patients [52,53].

After assessment with noninvasive tools, hemodynamic confirmation of PH by right heart catheterization (RHC) should be considered when severe PH
is suspected [13] or in the work-up to lung transplant or lung reduction surgery evaluation.

**PHENOTYPE PRESENTATION DURING DIAGNOSTIC WORK-UP**

According to a classical paradigm, the physiopathology of PH is fundamentally driven by that of COPD [54] and caused by obstruction to airflow and hypoxic vasoconstriction. It would follow that PH is an inevitable, almost mechanical consequence of severe obstructive disease [55]. Although these mechanisms have indeed been confirmed experimentally as having a relevant role in the pathogenesis of PH [56], other patterns of pulmonary vascular disease in COPD have emerged in recent years, suggesting a more complex interplay.

**RESPIRATORY FUNCTION AND HEMODYNAMIC PROFILES**

PH is usually somewhat proportional to the degree of airflow obstruction [9,57], and its rate of progression relatively slow [58,59] compared to other lung diseases [60,61], increasing by approximately 0.5 mmHg of mPAP per year. It is difficult to establish prevalence and natural history of PH in COPD because patients are not systematically referred for RHC due to its limited indications. However, evidence [58] shows that approximately 25% of COPD patients without PH at a given time will develop it after 5 years, with increased risk for those with higher mPAP at rest and during exercise. The development of PH is correlated with worsening of hypoxemia, which might provide a clue in the absence of worsening of COPD [58]. Recently, the concept of a specific vascular phenotype [1] has been put forth. This phenotype is characterized by severe hemodynamic compromise, moderate airflow obstruction, marked reduction in DLCO [62*] and severe hypoxemia, with normal arterial CO2 [11]. Thabut et al. [10] previously identified four clusters of COPD patients: patients without PH, with a moderate decrease in forced expiratory volume in one second (FEV1) and PaO2; patients with moderate PH, severe airflow obstruction and moderate hypoxemia; patients with severe airflow obstruction, severe hypoxemia and severe PH; and the PVP, with severe PH and hypoxemia but only moderate airflow obstruction. Thus, the level of hemodynamic compromise is not always proportional to that of the airflow obstruction, and patients with severe PH don’t always have mild airflow obstruction.

**IMAGING PATTERNS**

Due to the importance of early PH detection, research has focused on CT imaging, routinely performed on COPD patients. Although no correlation exists [9,57,63] between the extent of emphysema and PH severity, airway remodeling and pulmonary artery to aorta diameter ratio are proportional to the degree of PH [57,64] and in severe COPD patients a ratio >1 is predictive of PH [65]. Furthermore, patients with severe PH have increased remodeling of small pulmonary vessels on chest CT [66]. Finally, patients at earlier COPD stages and with milder emphysema present increased RV size and arterial pruning [27] than those with more advanced COPD, suggesting a similar profile to the PVP.

**HEMODYNAMIC STATUS, EXACERBATIONS AND EXERCISE CAPACITY**

PH (and even an mPAP >18 mmHg) is a risk factor for hospitalization from acute exacerbation of COPD [2]; furthermore, mortality in COPD patients with severe PH is increased with the severity and number of exacerbations requiring hospitalization in the previous year [62*]. Interestingly, COPD patients admitted for an ‘exacerbation’ episode may actually have decompensated heart failure from postcapillary PH [67].

PH decreases the exercise capacity of COPD patients, as evidenced by the six-minute walk test [68,69] and the cardio-pulmonary exercise test [70], independently from other concurring factors such as FEV1 or PaO2 [69] and particularly in patients who are not candidates for lung-transplant [71]. Furthermore, patients with severe PH present a cardiovascular limitation to exercise [53] rather than exhausted ventilatory reserve seen in COPD patients without and with moderate PH.

**OVERVIEW OF DIAGNOSIS AND MANAGEMENT ACCORDING TO PHENOTYPES**

PH can take many forms in COPD (Fig. 1), partly explaining its variable prevalence [8–10,72–74]. All COPD patients, regardless of hemodynamic status, should be treated according to guidelines including oxygen (if in respiratory failure), physiotherapy and optimal medical therapy. Once RHC confirms PH, to avoid missing potentially treatable forms, possible causes of PAH (autoimmune disease, HIV, liver disease, congenital heart defects, pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis and schistosomiasis) should be considered, and chronic thromboembolic PH ruled out. If all these hypotheses are discarded, PH associated with COPD might be considered.
In the following section we outline the different clinical scenarios where COPD can coexist with PH (Table 1).

**PULMONARY HYPERTENSION DURING EXERCISE**

Even in the absence of PH, COPD patients often suffer from systemic [75] and pulmonary [76] endothelial dysfunction. Abnormal hemodynamic response to exercise is common in COPD [58], and patients with mild COPD [22] and smokers without airflow obstruction [16] can develop pulmonary vascular remodeling, although it is unknown if and how these patients may progress to PH. Furthermore, elevation of mPAP during exercise might be a consequence of rising pulmonary capillary pressure from left heart dysfunction and only RHC can reliably distinguish the latter from pulmonary vascular remodeling [77]. Whatever the case, patients with PH during exercise are not candidates for treatment with pulmonary vasodilators; however, they should be monitored with echocardiography, especially during an otherwise unexplained worsening of symptoms or hypoxemia.

**MILD-MODERATE PRE-CAPILLARY PULMONARY HYPERTENSION**

One of the most common forms of PH in COPD, it is usually identified in later stages [8]; in these patients, endothelial dysfunction is even greater than in COPD without PH and accompanied by arterial stiffness [75], potentially explaining PH development. The clinical picture is thus characterized by severe or very severe airflow obstruction, moderate to severe hypoxemia, mild to moderate PH and ventilatory limitation to exercise.

**FIGURE 1.** Algorithm for diagnosis and management of PH in COPD according to phenotype. Right heart catheterization is mandatory only if severe PH is suspected or in the work-up to lung transplant or lung reduction surgery evaluation. Assess COPD severity and manage according to current recommendations [98]. 6th World Symposium on PH classification is considered for grouped PH [86]. CI, cardiac index; COPD, chronic obstructive lung disease; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; PH, pulmonary hypertension.
Pulmonary vasodilators are contra-indicated as they may have a detrimental effect on gas exchange [78]; in eligible patients, lung transplantation should be prioritized. Hemodynamic status should be monitored through echocardiography to detect the development of severe PH.

**POST-CAPILLARY PULMONARY HYPERTENSION**

Patients with COPD have increased cardiovascular risk [79] and COPD is a risk factor for cardiovascular events in patients with systemic hypertension [80]; even reduced lung function per se has the same effect [81]. It is therefore not surprising that COPD patients should present with PH due to left heart disease [82], frequent during exacerbations. A noteworthy cause of postcapillary PH in COPD patients is diastolic dysfunction, present in about half of moderate to severe COPD patients and correlated with exercise intolerance [83]. When probability of postcapillary PH is high [84] because of left heart disease or cardiovascular risk factors, RHC is not mandatory [85]. Since RHC is the only way to safely discriminate between pre and postcapillary PH, the prevalence of postcapillary PH in COPD is unknown, but RHC is not mandatory [85]. Since RHC is the only way to safely discriminate between pre and postcapillary PH, the prevalence of postcapillary PH in COPD is unknown, but pulmonary artery wedge pressure may be increased in >60% of COPD patients [9]. Postcapillary PH in COPD should be correctly categorized as group two of the PH Nice classification [86] and treated as such. There are no studies assessing the clinical characteristics and outcomes of combined pre and postcapillary PH in COPD.

**PULMONARY VASCULAR PHENOTYPE VERSUS CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION**

The PVP, with its characteristic profile of moderate airflow obstruction, severe hypoxemia and DL_{CO} reduction, cardiovascular limitation to exercise, and poor prognosis [11,63], constitutes a real diagnostic challenge. This clinical picture may indeed represent either the PVP or just the coincidence of rare idiopathic PAH (iPAH) with the highly

### Table 1. Clinical phenotypes characteristics and treatment recommendations.

| Phenotype                          | Characteristics                                                                 | Recommendations                                                                 |
|------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| PH during exercise                 | PAP abnormally rises during exercise                                          | Treat COPD and cardiovascular risk factors                                      |
|                                    | Related to vascular remodeling or left heart dysfunction                       | Pulmonary vasodilator not recommended                                           |
|                                    | Risk to develop PH at rest                                                   |                                                                                 |
| Postcapillary PH                   | RHC: mPAP ≥ 21 mmHg and PAWP ≥ 15 mmHg                                        | Treat COPD and cardiovascular risk factors                                      |
|                                    | Frequently mild PH                                                           | Treat heart failure and valve disease                                           |
|                                    | More cardiovascular risk factors                                              | Consider diuretics                                                             |
|                                    | Predominant LA enlargement                                                   | Consider low-sodium diet                                                        |
|                                    | LV diastolic or/and systolic dysfunction.                                     | Pulmonary vasodilator not recommended                                           |
|                                    | Mitral valve disease, less frequent aortic valve disease.                    |                                                                                 |
| Mild to moderate precapillary PH   | Frequent type of PH at rest in COPD patients                                  | Treat COPD                                                                     |
|                                    | More frequent in severe and very severe COPD                                  | Consider diuretics                                                             |
|                                    | More endothelial dysfunction and arterial stiffness                           | Pulmonary vasodilator not recommended                                           |
|                                    | Ventilatory limitation during exercise: low breathing reserve, increased PaCO₂ |                                                                                 |
| Pulmonary vascular phenotype       | Mild to moderate airflow obstruction [FEV₁ ≥ 60%] and severe PH [mPAP ≥ 35 mmHg or Cl < 2 L/min/m²] | Treat COPD                                                                     |
|                                    | Severe hypoxemia with no hypercapnia                                          | Consider diuretics                                                             |
|                                    | Severe DL_{CO} reduction                                                      | Refer to a PH reference center and consider inclusion in large clinical trial with pulmonary vasodilators |
|                                    | Cardiovascular limitation during exercise with low peak VO₂, lower PetCO₂    |                                                                                 |
| Severe COPD – Severe PH phenotype  | Severe airflow obstruction [FEV₁ < 50%] and severe PH [mPAP ≥ 35 mmHg or Cl < 2 L/min/m²] | Treat COPD                                                                     |
|                                    | Severe gas impairment                                                        | Consider diuretics                                                             |
|                                    | Increased mortality                                                          | Refer to a PH reference center and consider inclusion in specific clinical trial |

Cl, cardiac index; DL_{CO}, diffusing capacity of the lungs for carbon monoxide; FEV₁, forced expiratory volume in one second; LA, left atrium; LV, left ventricle; mPAP, mean pulmonary arterial pressure; PaCO₂, partial arterial pressure of carbon dioxide; PAWP, pulmonary artery occlusion pressure; PetCO₂, end-tidal carbon dioxide; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; UW, wood units; VO₂, oxygen consumption.
prevalent COPD in mild form[87]. This distinction, which might seem philosophical, has bearings on overall management since iPAH is treated with vasodilator drugs, for which there is no conclusive evidence in COPD patients with PH [1,88]; furthermore, it is unknown whether risk assessment scores and follow-up guidelines for iPAH apply to the PVP. Some clues from clinical studies [53,89], case series [90,91], and small randomized-controlled trials [92] point to this phenotype as a possible candidate for pulmonary vasodilators and patients should always be referred to an expert PH center for diagnosis and inclusion in a clinical trial and/or lung transplant workup.

In the debate on how to best distinguish between the PVP and the coincidence of iPAH and COPD, we propose that the severity of hypoxemia, and not that of airflow obstruction, might provide a clue to favor the diagnosis of PVP (Fig. 2; Table 1 supplementary material, http://links.lww.com/COPM/A31). Patients with iPAH rarely show more than mild hypoxemia, in contrast with the severe hypoxemia existing in the PVP. Although the proportion of patients with iPAH and COPD in published series is unknown [93,94,95*], obstructive disease is certainly not uncommon among iPAH patients [94] and despite being associated with a certain reduction in PaO2, the latter is rarely as severe as seen in case series of severe PH in COPD, in which PVP patients are included [10,11,62*,63,76,88,95*,96]. This proposal needs to be validated by future clinical and physiological studies.

**BEYOND THE PULMONARY VASCULAR PHENOTYPE: IS THERE A ‘SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE -SEVERE PULMONARY HYPERTENSION’ PHENOTYPE?**

Severe hemodynamic compromise is rare in clinically stable patients [8,39,97] and doesn’t always present with mild airflow obstruction, as in the PVP. In the study by Thabut et al., patients with severe COPD and severe PH formed a separate cluster from the PVP [10]; furthermore, two large registry cohorts [51**,95] described patients with severe PH and similar FEV1 to those with milder PH, indicating that patients with PVP (who normally have significantly higher FEV1 than mild PH patients) were lumped together with patients with severe hemodynamic compromise and severe airflow obstruction. Interestingly, in the last of those studies [51**], patients with advanced COPD stages and severe

![Figure 2](image_url)

**FIGURE 2.** Relationship between PaO2, mPAP and FEV1 in COPD patients with severe PH (SPH-COPD) and in pulmonary arterial hypertension (PAH). Each bubble represents the relationship of mean values of mPAP and PaO2 reported in case series of SPH-COPD [10,11,62*,63,88,95*,96] and PAH [93,94,95*]. The diameter of bubbles is proportional to the FEV1 reported in the same studies. Patients with COPD and severe PH are consistently more hypoxemic than PAH regardless of hemodynamic severity. Thus, when mild-moderate COPD is observed, PaO2 may be more helpful than FEV1 in differentiating patients with PVP over concurrent mild-moderate COPD and PAH. FEV1, forced expiratory volume in one second; mPAP, mean pulmonary artery pressure; PAH, idiopathic pulmonary arterial hypertension; PaO2, arterial oxygen partial pressure; PVP, pulmonary vascular phenotype; SPH-COPD, COPD and severe PH.
PH presented the worst survival, suggesting the importance of singling out this phenotype.

What factors favor the development of mild versus severe PH in patients with severe obstructive disease? As mentioned, the severity of emphysema is not correlated with hemodynamic compromise [9,57,63], and postcapillary was carefully excluded in works studying this group of patients [10,51**,95**]. Interestingly, studies using mPAP ≥40 mmHg as definition for severe PH [11,63] properly identified patients with the PVP, since their FEV₁ was significantly higher than in the moderate PH group; this suggests that a higher mPAP threshold might be a better discriminant for the PVP. Recently it has been shown [4**] that PVR >4 WU may be associated with poorer outcomes in COPD and thus a better descriptor of severe PH, but whether these patients conform to the PVP (statistically higher FEV₁, lower PaO₂ compared to patients with PVR ≤4 WU) is unknown. Finally, patients with severe PH and severe obstructive disease were included in a small randomized controlled trial showing positive results with pulmonary vasodilators in severe PH [92]. Overall, studies focusing on this specific phenotype of patients separately from the PVP may be warranted to evaluate its clinical presentation and outcomes.

FUTURE DIRECTIONS

Preliminary data focusing on severe PH patients have been encouraging and these patients may be a good target for future, dedicated large clinical trials with pulmonary vasodilators; it may also be useful to distinguish between the PVP and the ‘severe COPD-severe PH’ phenotype. Furthermore, the role of hypoxemia in the PVP versus iPaH should be investigated (Fig. 2).

Future studies should address the variety of presentations of PH in COPD (Table 1, Fig. 1) by focusing on deeply phenotyped cohorts, comparing clinical presentation and outcomes, harnessing registries to increase reproducibility with larger cohorts, and concentrating pharmacological trials on likely candidate phenotypes with carefully targeted compounds.

CONCLUSION

PH associated with COPD may present in a variety of phenotypes that require careful investigation, individualized management and, in the case of severe hemodynamic compromise, referral to an expert PH center. All patients require optimal management of their underlying condition; PH in COPD should also elicit referral to a lung transplant center in eligible patients. There is still not enough evidence favoring the use of pulmonary vasodilators in PH associated with COPD, likely due to insufficient discrimination between previously unrecognized phenotypes with different responses to therapy in historical randomized clinical trials.

Acknowledgements

None.

Financial support and sponsorship

None.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2020; 58:1801914.
2. Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:158–164.
3. Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367:913–921.
4. Zeder K, Avian A, Bachmaier G, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58:2100444. This study found PVR >5 WU to be the strongest independent hemodynamic predictor of mortality in COPD patients and may best identify COPD patients with severe pulmonary vascular disease.
5. Gall H, Felix JF, Schreck FK, et al. The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. J Heart Lung Transplant 2017; 36:957–967.
6. Hurdman J, Cordifffe R, Elliot CA, et al. ASPIRE registry: assessing the spectrum of pulmonary hypertension identified at a. Eur Respir J 2012; 39:945–958.
7. Andersen KH, Hjersen M, Kjegaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012; 31:373–380.
8. Portillo K, Toralba Y, Blanco I, et al. Pulmonary hemodynamic profile in chronic obstructive pulmonary disease. Int J COPD 2015; 10:1313–1320.
9. Scharf SM, Iqbal M, Keller C, et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166:314–322.
10. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127:1531–1536.
11. Chaouat A, Bugnet AS, Kadaou N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172:189–194.
12. Chebib N, Mornex JY, Tractel J, et al. Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups. Pulm Circ 2018; 8:2045894018775056.
13. Kovacs G, Agusti A, Barberà JA, et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease is there a pulmonary vascular phenotype? Am J Respir Crit Care Med 2018; 198:1000–1011.
14. Newman JH, Rich S, Abman SH, et al. Enhancing insights into pulmonary vascular disease through a precision medicine approach: a joint nhbi-cardiovascular medical research and education fund workshop report. Am J Respir Crit Care Med 2017; 195:1661–1670.
15. Barnes JW, Tonelli AR, Heresi GA, et al. Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 grover conference series). Pulm Circ 2016; 6:439–447.
16. Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodeling in smokers and patients with mild COPD. Eur Respir J 2002; 19:632–638.
Disorders of the pulmonary circulation

17. Bunel V, Guyard A, Daurat G, et al. Pulmonary arterial histologic lesions in patients with COPD with severe pulmonary hypertension. Chest 2019; 158:33–44.

18. Ferrer E, Pinaida VI, Castañeda J, et al. Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig. Eur Respir J 2011; 38:617–627.

19. Sakao S, Voelkel NF, Tatsumi K. The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations. Eur Respir Rev 2014; 23:350–355.

20. Simeoni M, Paravá N, Pich A, et al. Inducible NO inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011; 147:293–305.

21. Peinado VI, Gómez FP, Barbera JA, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Eur J Cardiovasc Prev Rehabil 2005; 12:389–394.

22. Washko GR, Nardelli P, Ash et al. Arterial vasoconstricting, right ventricular size, and clinical outcomes in chronic obstructive pulmonary disease: a longitudinal observational study. Am J Respir Crit Care Med 2019; 200:446–461.

23. Synn AJ, Margerie-Mellon CD, Jeong SY, et al. Effects of cigarette smoke on the small pulmonary arteries and measures of vascular pruning on computed tomography. Pulm Circ 2021; 11:20458940211061284.

24. Blanco I, Piccari L, Barbera JA. Pulmonary vasculature in COPD: the silent component. Respir Res 2016; 18:944–994.

25. Weissman N, Lobso P, Pich A, et al. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med 2014; 189:1359–1373.

26. Hoepfer MM, Yonk-Noordegraaf A. Is there a vanishing pulmonary capillary syndrome? Lancet Respir Med 2017; 5:676–678.

27. Pak O, Aldashev A, Welsh D, Peacock A. The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J 2007; 30:464–472.

28. Sakao S, Tatsumi K, Voelkel NF. Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Crit Care Med 2001; 164:219–224.

29. Heath D, Williams D, Rios-Dalence J, et al. Small pulmonary arterial vessels of Agnara Indians from the Bolivian Andes. Histopathology 1990; 16:565–571.

30. Neurath MW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019; 53:1801189.

31. Neubert L, Borchorst P, Stark H, et al. Molecular profiling of vascular remodeling in chronic pulmonary disease. Am J Pathol 2020; 190:1382–1396.

32. Hoffmann J, Nolte IM, Marsh LM, et al. Distinct differences in the expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension. Respir Res 2011; 12:99–111.

33. Hoffmann J, Wilhelms O, Oschewe AW, Kwapiszewska G. Microarray analysis in pulmonary hypertension. Eur Respir J 2016; 48:229–241.

34. Chauvat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32:1571–1585.

35. Braganza M, Shaw J, Solverson K, et al. Chronic obstructive pulmonary disease with pulmonary hypertension: A systematic review and meta-analysis. Clin Respir J 2022; 16:276–283.

36. Iyer AS, Wells JM, Vishin S, et al. CT scan measured pulmonary artery to aorta ratio and echocardiography for determining pulmonary hypertension in severe COPD. Chest 2014; 145:824–832.

37. Coste F, Doumes G, Dromer C, et al. CT evaluation of small pulmonary vessels area in patients with COPD with severe pulmonary hypertension. Thorax 2016; 71:830–837.

38. Krahne JS, Abraham WT, Adamson PB, et al. Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. J Card Fail 2015; 21:240–249.

39. Cugno M, Kalhan R, Seldin DW, et al. Catecholamine and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010; 104:1877–1882.

40. Blanco I, Valero R, Torres-Castro R, et al. Effects of pulmonary hypertension on exercise capacity in severe COPD patients. Eur J Pulm Vasc Dis 2014; 20:201–208.

41. Coste F, Benílala I, Doumes G, et al. Assessing pulmonary hypertension in COPD. Is there a role for computed tomography? Int J Chron Obstruct Pulmon Dis 2019; 14:2065–2079.

42. Leuchte HH, Baumgartner RA, et al. Nounou M, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173:744–750.

43. Hawkins NM, Kholsa A, Vranisa SA, et al. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med 2017; 17:11.

44. Tian F, Song W, Wang L, et al. NT-proBNP in AECOPD-PH: old biomarker, new insights based on a large retrospective case-controlled study. Respir Res 2021; 22:321.

45. Kovacs G, Avian A, Bachmaier G, et al. Severe Pulmonary Hypertension in COPD. Chest 2022; 160:1269–1277.

46. Barbera JA, Riverola A, Roca J, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 149:423–429.

47. Torres-Castro R, Gimeno-Santos E, Vilaró J, et al. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis. Eur Respir Rev 2021; 30:2000321.
Emerging phenotypes of pulmonary hypertension associated with COPD García and Piccari

72. Weitenblum E, Sautegeau A, Ehhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131:493–498.
73. Oswald-Mammoser M, Weitenblum E, Quix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107:1193–1198.
74. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28:523–532.
75. Piccari L, Pozzo RdeI, Blanco I, et al. Association between systemic and pulmonary vascular dysfunction in COPD. Int J COPD 2020; 15:2097–2047.
76. Domingo E, Grignola JD, Aguilar R, et al. Pulmonary arterial wall disease in COPD and interstitial lung diseases candidates for lung transplantation. Resp Res 2017; 18:85.
77. Herve P, Lau EM, Silton O, et al. Criteria for diagnosis of exercise pulmonary hypertension. Eur Respir J 2015; 46:728–737.
78. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181:270–278.
79. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Lancet Respir Med 2015; 3:631–639.
80. Perticone M, Maio R, Caroleo B, et al. COPD significantly increases cerebral and cardiovascular events in hypertensives. Sci Rep 2021; 11:7884.
81. Ramalho SHR, Shah AM. Lung function and cardiovascular disease: a link. Trends Cardiovasc Med 2021; 31:93–98.
82. Lepida D, Papathanasiou A, Galatou E, et al. The contribution of left heart disease in COPD patients with pulmonary hypertension. Hellenic J Cardiol 2018; 59:160–165.
83. Faludi R, Hadju M, Vertes V, et al. Diastolic Dysfunction Is a Contributing Factor to Exercise Intolerance in COPD. COPD 2018; 13:345–351.
84. Vachery JL, Tedford RJ, Rosenzweig S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53:1801897.
85. Kanwar MK, Tedford RJ, Thenappan T, et al. Elevated pulmonary pressure noted on echocardiogram: a simplified approach to next steps. J Am Heart Assoc 2021; 10:e017684.
86. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53:1801913.
87. Blanco I, Tura-Cede O, Peinado V, Barberà JA. Updated perspectives on pulmonary hypertension in COPD. Int J COPD 2020; 15:1315–1324.
88. Girard A, Jouveau S, Chabanne C, et al. Severe pulmonary hypertension associated with COPD: Hemodynamic improvement with specific therapy. Respiration 2015; 90:220–228.
89. Brewis MJ, Church AG, Johnson MK, Peacock AJ. Severe pulmonary hypertension in lung disease: phenotypes and response to treatment. Eur Respir J 2015; 46:1378–1389.
90. Abuserewa ST, Selim A, Youssef A, Zolty R. Role of selexipag in chronic obstructive pulmonary disease (COPD) patients with out-of-proportion pulmonary hypertension. Cureus 2021; 13:e16520.
91. Calcaianu G, Canuet M, Schuller A, et al. Pulmonary arterial hypertension-specific drug therapy in COPD patients with severe pulmonary hypertension and mild-to-moderate airflow limitation. Respiration 2016; 91:9–17.
92. Vitulo P, Stanzola A, Confolonien M, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. J Heart Lung Transplant 2017; 36:166–174.
93. Stubbe B, Seyfarth HJ, Kleymann J, et al. Monotherapy in patients with pulmonary arterial hypertension at four German PH centres. BMC Pulm Med 2021; 21:130.
94. Hoepf MM, Pausch C, Grünig E, et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant 2020; 39:1435–1444.
95. Vizza CD, Hoepf MM, Huscher D, et al. Pulmonary hypertension in patients with COPD: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Chest 2021; 160:678–689.
96. This analysis of the COMPERA registry reports that male sex, low exercise tolerance and high PVR are predictors of death in COPD-PH, and that PH-targeted therapy may improve exercise capacity and functional class in a subgroup of patients with severe COPD-PH.
97. Taniabe N, Tanguchi H, Tsuijno I, et al. Multinstitutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respiratory 2015; 20:805–812.
98. Hoepf MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4:306–322.
99. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GCLD Executive Summary. Am J Respir Crit Care Med 2017; 195:557–582.